European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Study efficacy measures will include the expression of dystrophin protein and motor function.
Subscribe To Our Newsletter & Stay Updated